We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Reduced clone size upon BTK inhibitor resistance mutations relates to toxicity caused by inherited PLCG2 gain‐of‐function variations.
- Authors
Smith, C. I. Edvard; Zain, Rula
- Abstract
This article discusses the relationship between resistance mutations in the BTK and PLCG2 genes and the clone size in chronic lymphocytic leukemia (CLL) patients treated with Bruton's tyrosine kinase inhibitors (BTKi). The study found that patients with acquired PLCG2 gain-of-function mutations had significantly reduced clone sizes compared to those with BTK mutations. The authors propose that the expression of constitutively active PLCG2 protein in CLL cells comes at a cost, leading to reduced clone sizes. The identification of these reduced clone sizes suggests the possibility of novel targeted tumor therapies. The study was supported by grants from the Swedish Cancer Society, the Swedish County Council, and the Center for Innovative Medicine.
- Subjects
BRUTON tyrosine kinase; MOLECULAR cloning; ANIMAL cloning; AGAMMAGLOBULINEMIA; GENETIC mutation
- Publication
European Journal of Haematology, 2024, Vol 113, Issue 1, p130
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.14204